{
  "label": "q_cs03_q11_longitudinal",
  "artifact_type": "question",
  "artifact_id": "sha256:c38bc9a68521c9c8ed7892ef086d3ebf21fed43e27e82c139e1ca353daae5f9e",
  "input_ids": [
    "sha256:b4ba5337b06c8de68ac3315db1a4f6980c5bd48efd529c3914f30297d6afd329",
    "sha256:bd89cf127fe8ce28af2609c702fd06647b82347034cf0bfb835b2f19a4d19bd1",
    "sha256:044266001cadd958fbee4c3c26f47dd870c06eeeaffdc51d0bcca59d174fce62",
    "sha256:526bf0877b15ba594954d8544c6493f2535bc8acb2239824a0eeeb941d801b2d"
  ],
  "prompt_id": null,
  "model_config": null,
  "created_at": "2026-02-17T12:01:44.859911",
  "content": "{\n  \"question_id\": \"cs03_q11_longitudinal\",\n  \"scope_id\": \"clinical_signal_03\",\n  \"checkpoint_after\": 20,\n  \"question_type\": \"longitudinal\",\n  \"prompt\": \"What is the emerging safety profile of LNS-4821, and which patient subgroup is most affected?\",\n  \"ground_truth\": {\n    \"canonical_answer\": \"Hepatotoxicity in the statin co-administered subgroup. ALT elevations reaching 2-3x ULN across multiple sites, with two subjects meeting Hy's Law criteria. Non-statin patients remain stable. The cross-site distribution rules out the Site 07 equipment hypothesis.\",\n    \"required_evidence_refs\": [\n      \"clinical_signal_03_ep_017\",\n      \"clinical_signal_03_ep_018\",\n      \"clinical_signal_03_ep_019\"\n    ],\n    \"key_facts\": [\n      \"ALT elevations are concentrated in subjects receiving concurrent statin therapy, with higher-dose statin subgroups showing proportionally greater enzyme increases\",\n      \"multi-site signal distribution rules out site-specific confounders as causal explanation\",\n      \"the hepatic enzyme pattern is consistent with a drug-drug interaction mediated through shared hepatic metabolism pathways, not direct hepatotoxicity\",\n      \"Site 07 lab equipment issue is not the cause of ALT elevations\",\n      \"the ALT elevation pattern correlates with statin co-administration timing, not with immune activation or antibody response patterns\",\n      \"musculoskeletal safety endpoints track within expected ranges, confirming the safety signal is organ-specific to the liver\",\n      \"ALT elevations appeared progressively over multiple weeks of statin co-administration with onset timing correlating with cumulative exposure duration rather than a single acute event\",\n      \"the adverse signal is hepatic (ALT/AST elevation), not renal \\u2014 kidney function markers remain stable while liver enzymes diverge\"\n    ]\n  }\n}",
  "metadata": {
    "question_id": "cs03_q11_longitudinal",
    "question_type": "longitudinal",
    "checkpoint_after": 20,
    "scope_id": "clinical_signal_03",
    "layer_name": "questions",
    "layer_level": 3,
    "build_fingerprint": {
      "scheme": "synix:build:v1",
      "digest": "2146a331afc2ce975569f72d99b9dbf2d788bc62a3ca2f8966715a71d32b5f27",
      "components": {
        "transform": "a7d463dc476b419c96a5f454f481b455ca81a8d8ee3904631b7729963317406f",
        "inputs": "cc89110a27a4a530"
      }
    },
    "transform_fingerprint": {
      "scheme": "synix:transform:v2",
      "digest": "a7d463dc476b419c96a5f454f481b455ca81a8d8ee3904631b7729963317406f",
      "components": {
        "transform_id": "3176c030aaa3a69e",
        "source": "929fe273ac2dab06",
        "model": "1e2ccf75e96d7ee7"
      }
    }
  }
}